New hope for kidney transplant patients: experimental drug aims to prevent rejection
NCT ID NCT07508787
First seen Apr 06, 2026 · Last updated May 03, 2026 · Updated 2 times
Summary
This study tests a new medicine called siplizumab to see if it can help prevent kidney transplant rejection better than a standard treatment. About 120 adults getting a kidney transplant will receive either siplizumab or the usual anti-rejection drug, along with standard anti-rejection medications. Researchers will monitor participants for one year to check for side effects and how well the kidney is working.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL TRANSPLANT FAILURE AND REJECTION are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.